Histone deacetylase 10, a potential epigenetic target for therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Histone deacetylase 10 (HDAC10), a class II enzyme, is implicated in numerous tumor and non-tumor diseases.
• Its roles in epigenetic regulation and signaling pathways are critical in cellular processes.

Purpose of the Study:

• To review the biological functions, mechanisms, and inhibitors of HDAC10.
• To highlight HDAC10 as a potential therapeutic target for various diseases.

Main Methods:

• Literature review of studies on HDAC10.
• Analysis of HDAC10's involvement in cancer and non-cancerous conditions.
• Examination of existing and potential HDAC10 inhibitors.

Main Results:

• HDAC10 plays significant roles in cancer progression and non-tumor diseases like IgA nephropathy and HIV infection.
• Few specific HDAC10 inhibitors have been developed to date.
• HDAC10's diverse functions make it a promising target for drug development.

Conclusions:

• HDAC10 is a key therapeutic target for both oncological and non-oncological conditions.
• Further research into HDAC10 biology and inhibitor development is warranted.
• Targeting HDAC10 offers potential clinical utility across a spectrum of diseases.